MedRhythms

MedRhythms occupies a specialized position at the intersection of digital therapeutics, neurorehabilitation, and medical devices. Its focus is narrower than general digital-health platforms because the company targets mobility impairments associated with stroke, Parkinson’s disease, and other neurological conditions rather than broad chronic-care management. The main differentiator is the integration of rhythmic auditory stimulation, real-time gait sensing, personalized music, and adaptive algorithms into prescription products such as InTandem and Movive. This creates a product model that combines software, wearable or sensor inputs, therapeutic content, and clinical evidence. The 2025 national distribution agreement with Edwards Health Care Services gives MedRhythms a channel advantage beyond direct clinical development, particularly across Medicare, VA, and commercial insurance settings. Specific competitor comparisons are not supported by the available company record, so MedRhythms’ relative market share and competitive standing remain difficult to quantify. Its $57.3 million funding base and FDA-authorized product indicate substantially greater commercialization maturity than an early research-stage venture.

MedRhythms’ trajectory shows a long transition from research-led development to regulated product commercialization. Founded in 2013, the company built its platform around music, sensors, software, and neuroscience, then raised $5.3 million in Series A funding in 2018. Its financing accelerated in 2021, when two Series B transactions totaled $27 million and included Advantage Capital, Morningside, and Bose Ventures. Additional venture financing of $19.8 million in December 2023 and $3.25 million in March 2026 extended the capital base, although the detailed round list contains 10 disclosed entries versus a stated 13 total rounds. Product expansion is the clearest operating inflection point: InTandem addresses chronic stroke-related walking impairment, while Movive broadens the company’s reach into Parkinson’s rehabilitation following its 2025 FDA Class II listing. The 2025 appointments of Joel Behnke and Larry Jasinski, followed by a national distribution agreement in September 2025, signal a shift toward sales execution, reimbursement access, and scaled deployment.